WASHINGTON TRUST Co Raises Stock Position in Danaher Corporation $DHR

WASHINGTON TRUST Co boosted its holdings in shares of Danaher Corporation (NYSE:DHR) by 15.0% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,771 shares of the conglomerate’s stock after purchasing an additional 623 shares during the period. WASHINGTON TRUST Co’s holdings in Danaher were worth $942,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors have also modified their holdings of the stock. Pacific Capital Partners Ltd purchased a new stake in Danaher in the 1st quarter worth approximately $7,175,000. Larson Financial Group LLC increased its holdings in Danaher by 154.1% in the first quarter. Larson Financial Group LLC now owns 5,517 shares of the conglomerate’s stock valued at $1,131,000 after buying an additional 3,346 shares in the last quarter. Allen Capital Group LLC raised its position in shares of Danaher by 38.7% in the first quarter. Allen Capital Group LLC now owns 2,059 shares of the conglomerate’s stock worth $422,000 after acquiring an additional 574 shares during the period. Mayflower Financial Advisors LLC boosted its stake in shares of Danaher by 12.3% during the 1st quarter. Mayflower Financial Advisors LLC now owns 2,846 shares of the conglomerate’s stock worth $583,000 after acquiring an additional 312 shares in the last quarter. Finally, Montis Financial LLC grew its position in shares of Danaher by 14.5% during the 1st quarter. Montis Financial LLC now owns 1,756 shares of the conglomerate’s stock valued at $360,000 after acquiring an additional 223 shares during the period. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

DHR has been the topic of several research analyst reports. Rothschild Redb lowered Danaher from a “strong-buy” rating to a “hold” rating in a report on Wednesday, October 8th. Wall Street Zen lowered Danaher from a “buy” rating to a “hold” rating in a research report on Monday. Wells Fargo & Company reissued a “positive” rating on shares of Danaher in a report on Thursday, October 23rd. Barclays upped their price objective on shares of Danaher from $225.00 to $250.00 and gave the stock an “overweight” rating in a research report on Wednesday, October 22nd. Finally, Deutsche Bank Aktiengesellschaft boosted their target price on shares of Danaher from $235.00 to $250.00 and gave the stock a “buy” rating in a research note on Wednesday, October 22nd. Eighteen research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to data from MarketBeat, Danaher currently has a consensus rating of “Moderate Buy” and an average target price of $243.39.

Insider Transactions at Danaher

In other news, Director Teri List sold 2,778 shares of the firm’s stock in a transaction on Friday, August 22nd. The stock was sold at an average price of $211.06, for a total transaction of $586,324.68. Following the completion of the transaction, the director directly owned 20,751 shares in the company, valued at $4,379,706.06. This trade represents a 11.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, SVP Georgeann Couchara sold 5,174 shares of the firm’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $210.42, for a total value of $1,088,713.08. Following the transaction, the senior vice president owned 2,625 shares of the company’s stock, valued at $552,352.50. This trade represents a 66.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders have sold 29,728 shares of company stock worth $6,448,990. 11.20% of the stock is currently owned by insiders.

Danaher Price Performance

NYSE:DHR opened at $221.50 on Friday. Danaher Corporation has a one year low of $171.00 and a one year high of $258.23. The stock has a market cap of $156.46 billion, a PE ratio of 45.67, a P/E/G ratio of 3.28 and a beta of 0.81. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.10 and a current ratio of 1.52. The stock has a 50 day moving average price of $205.21 and a 200 day moving average price of $200.91.

Danaher (NYSE:DHR) last released its quarterly earnings data on Monday, October 20th. The conglomerate reported $1.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.72 by $0.17. The firm had revenue of $6.05 billion during the quarter, compared to analysts’ expectations of $6 billion. Danaher had a net margin of 14.44% and a return on equity of 10.92%. Danaher’s revenue was up 4.4% compared to the same quarter last year. During the same period last year, the business earned $1.71 earnings per share. Equities research analysts expect that Danaher Corporation will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Friday, October 31st. Stockholders of record on Friday, September 26th were paid a $0.32 dividend. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.6%. The ex-dividend date of this dividend was Friday, September 26th. Danaher’s payout ratio is 26.39%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.